Search results
Results from the WOW.Com Content Network
Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. [44]
Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]
Fentanyl is a highly potent synthetic piperidine opioid primarily used as an analgesic.It is 30 to 50 times more potent than heroin and 100 times more potent than morphine; [11] its primary clinical utility is in pain management for cancer patients and those recovering from painful surgeries.
The law (TN Code 53-11-311) that prevents nurse practitioners (NPs) or physician assistants (PAs) from prescribing more than 16 milligrams of buprenorphine-naloxone daily (despite standard dosing ...
There are fewer than 2,000 opioid treatment programs across the entire country, and as of 2018, 80% of U.S. counties lacked a single clinic. Patients lucky enough to live near one are required ...
McKinsey & Company agreed to pay $650 million to resolve criminal and civil investigations into its advice to opioids manufacturer ... at Le Bourget Airport near Paris, France, June 21, 2023 ...
In June 2017, the FDA asked the manufacturer to remove its long-acting form of oxymorphone (Opana ER) from the US market, because the drug's benefits may no longer outweigh its risks, this being the first time the agency has asked to remove a currently marketed opioid pain medication from sale due to public health consequences of non-medical use.
McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work to help opioids manufacturer Purdue Pharma boost the sales of the highly addictive ...